Assessment of Homologous Recombination Deficiency in Ovarian Cancer

Vikas Garg¹, Amit M Oza^{1

2}

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
² Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

PMID: 37347464
DOI: 10.1158/1078-0432.CCR-23-0563

Comment

Assessment of Homologous Recombination Deficiency in Ovarian Cancer

Vikas Garg et al. Clin Cancer Res. 2023.

. 2023 Aug 15;29(16):2957-2960.

doi: 10.1158/1078-0432.CCR-23-0563.

Authors

Vikas Garg¹, Amit M Oza^{1

2}

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
² Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

PMID: 37347464
DOI: 10.1158/1078-0432.CCR-23-0563

Abstract

Accurately assessing homologous recombination deficiency (HRD) to use as a predictive biomarker is an area of intense research in ovarian cancer. Validated assays have demonstrated utility in determining maintenance therapy following platinum sensitive chemotherapy. Novel functional assays promise the potential to reflect HRD in real time and predict response to PARP inhibitors. See related articles by Pikkusaari et al., p. 3110 and Blanc-Durand et al., p. 3124.

PubMed Disclaimer

Comment on

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UM, Lassus H, Hautaniemi S, Färkkilä A, Hynninen J, Hietanen S, Carpén O, Kauppi L. Pikkusaari S, et al. Clin Cancer Res. 2023 Aug 15;29(16):3110-3123. doi: 10.1158/1078-0432.CCR-22-3156. Clin Cancer Res. 2023. PMID: 36805632 Free PMC article.
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, Le Formal A, Pautier P, Michels J, Kfoury M, Hervé R, Mengue S, Wafo E, Elies A, Miailhe G, Uzan J, Rouleau E, Leary A. Blanc-Durand F, et al. Clin Cancer Res. 2023 Aug 15;29(16):3124-3129. doi: 10.1158/1078-0432.CCR-22-3328. Clin Cancer Res. 2023. PMID: 37067532

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Assessment of Homologous Recombination Deficiency in Ovarian Cancer

Affiliations

Assessment of Homologous Recombination Deficiency in Ovarian Cancer

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical